Lead Sponsor

Université de Sherbrooke

Age

45 - 80 years

Sex

ALL

Healthy Volunteers

Yes

•For healthy subjects: fasting glucose \< 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose \< 7.8 mmol/l and HbA1c \< 5.8%
•For subject with glucose intolerance (IGT): 2-hour post 75g OGTT glucose at 7.8-11.1 mmol/l on two separate occasions and HbA1c of 6.0 to 6.4%

•overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG
•treatment with a fibrate, thiazolidinedione, beta-blocker or other drug known to affect lipid or carbohydrate metabolism (except statins, metformin, and other antihypertensive agents that can be safely interrupted)
•presence of liver or renal disease, uncontrolled thyroid disorder, previous pancreatitis, bleeding disorder, or other major illness
•smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day
•prior history or current fasting plasma cholesterol level \> 7 mmol/l or fasting TG \> 6 mmol/l
•any other contraindication to temporarily interrupt current meds for lipids or hypertension
•being pregnant
•not be barren

Related studies

NCT07286747 · Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

NCT07440147 · Obesity & Overweight, Circadian Rhythm Disorders, and more

NCT02969798 · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), and more

NCT06964620 · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance

NCT05873322 · Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Induced Diabetes Mellitus, and more

Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)